The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Celgene; GlycoMimetics
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
 
Alain Patrick Algazi
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Oncosec (Inst)
 
James Moon
No Relationships to Disclose
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Roger Lo
No Relationships to Disclose
 
Kari Lynn Kendra
No Relationships to Disclose
 
Christopher D. Lao
No Relationships to Disclose
 
Karl D. Lewis
No Relationships to Disclose
 
Rene Gonzalez
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Celldex (Inst); Checkmate Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Reata Pharmaceuticals (Inst); Syndax (Inst); Takeda (Inst)
 
Kevin Kim
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
 
John E. Godwin
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb
Speakers' Bureau - Abbvie/Genentech; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Macrogenics (Inst); MedImmune (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie/Genentech; Bristol-Myers Squibb
 
Brendan D. Curti
Honoraria - Prometheus
Speakers' Bureau - Bristol-Myers Squibb; Prometheus
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Prometheus (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Agonox; Prometheus
 
Megan Othus
No Relationships to Disclose
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis